Role of Coronary CTA on Lipid Management and Risk Factors Control in an Asymptomatic Chinese Population

Launched by ZHANG LONGJIANG,MD · Feb 2, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new way to help prevent heart disease in people who do not have any symptoms but may be at risk due to factors like high cholesterol. Researchers want to see if using a special imaging test called coronary computed tomography angiography (CCTA) can improve the treatment for lowering cholesterol and managing other risk factors better than traditional methods, which usually rely on a risk score to guide treatment.

The trial is looking for residents of Nanjing aged 40 to 69 who do not have any known heart diseases and are able to understand and consent to participate. Participants should not have serious liver or kidney issues, and they should not have used certain cholesterol-lowering medications in the past. If you join the study, you can expect to undergo the CCTA test and receive personalized care aimed at improving your heart health. This research could help shape future heart disease prevention strategies, making it an important opportunity for potential participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Nanjing residents who have no plans to leave in the next 5 years
• • 2. Aged from 40 to 69 years
• • 3. Free of any known clinically cardiovascular disease Able to comprehend and sign an informed consent form
• Exclusion Criteria:
• • 1. Serious liver dysfunction, defined as AST or ALT \> 3 times the normal upper limit
• • 2. Chronic kidney disease (CKD) \> stage 4, defined as eGFR \< 30 ml/min/1.73 m2
• • 3. Prior CCTA or invasive coronary angiography within the last 5 years
• • 4. Any contraindications for CCTA
• • 5. Previous use of statin or non-statin lipid-lowering medication (such as ezetimibe, PCSK9 inhibitor and XueZhiKang)
• • 6. Life expectancy \< 3 years
• • 7. Other reasons the researcher deems inappropriate to attend